Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2015

View Archived Issues

New models of neurological disorders using genetic manipulation described

Evotec collaborates with Beyond Batten Disease Foundation

Kite Pharma enters into license agreement with the NIH for TCR-based products

HighTide Biopharma starts phase I trial of antidiabetic candidate HTD-4010

Novel PSMA ligand shows promise as a theranostic for prostate cancer

Tofacitinib is beneficial in treating atopic dermatitis in phase IIa study

AFA-19 mitigates neuropathic pain and reduces PTZ-induced seizures in mice

NeoGenomics to acquire Clarient

UT Austin receives Gates Foundation grant to study hu1B7 as pertussis prophylaxis

Takeda initiates phase I study of TAK-831 in development for schizophrenia and cerebellar ataxia

CFFT awards grant to Southern Research to identify drugs for rare CF variants

KemPharm completes intranasal abuse liability trial of KP-201/acetaminophen

Zydus Research Centre presents new anticancer compounds

Model allows testing of fecal microbiota transplantation for Clostridium difficile infection

Glycolysis inhibitor WP-1122 has additional effects on glioblastoma cells

Chugai Pharmaceutical profiles progress of third quarter 2015

Minomic signs agreement enabling clinical trial of cancer imaging agent

Bayer Schering Pharma patents MMP-12 inhibitors

Huabo Biopharm describes new recombinant bifunctional fusion protein

Sanofi develops GDIR agonists

Lupin reports BTK inhibitors

Janssen Pharmaceutica discloses EEF2K and/or PIK3C3 inhibitors

Genvoya noninferior to Stribild in phase III studies in treatment-naive adults with HIV infection

FDA approves Merrimack's liposomal irinotecan for pancreatic cancer

Ocular Therapeutix reports trial results for OTX-TP and Dextenza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...